isoxazoles has been researched along with Malignant Melanoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Jęśkowiak, I; Mączyński, M; Szeląg, A; Wiatrak, B | 1 |
| Janeczek, M; Jawień, P; Jęśkowiak-Kossakowska, I; Krzyżak, E; Mączyński, M; Szafran, R; Szeląg, A; Wiatrak, B | 1 |
| Bařinka, C; Hadley, M; Knox, T; Kozikowski, AP; Noonepalle, S; Pavlicek, J; Robers, MB; Shen, S; Tavares, MT; Ustinova, K; Villagra, A; Zhang, G; Zimprich, CA | 1 |
| de Castro Araujo, BL; de Melo, AC; de Oliveira, JL; Noguera, WS; Rezende, JFN; Thuler, LCS | 1 |
| Al-Abed, Y; Birmpilis, AI; Cheng, KF; Crichlow, GV; Ioannou, K; Lolis, EJ; Tsitsilonis, OE | 1 |
| Divate, D; Gangurde, S; Pawar, S; Pund, S | 1 |
| Barbagallo, I; Li Volti, G; Onni, T; Parenti, R; Pepe, F; Tibullo, D; Vanella, L; Zappalà, A | 1 |
| Benítez, S; Cabiscol, E; Dolcet, X; Domingo, M; Maiques, O; Marti, RM; Martinez, M; Matias-Guiu, X; Ribera, J; Santacana, M; Valls, J; Vea, A; Vilella, R; Yeramian, A | 1 |
| Burke, CJ; Cech, J; Chen, F; Datta, S; Granter, S; Kaufman, C; Kramer, M; Langdon, E; Lin, CY; Long, HK; Morrison, S; Mosher, J; Neuberg, D; Rahl, PB; Ratanasirintrawoot, S; Tomlinson, ML; Wheeler, GN; White, RM; Young, RA; Zon, LI | 1 |
| Asensi, M; Brown, BD; Cerdá, M; Estrela, JM; Mena, S; Obrador, E; Ortega, A; Petschen, I; Priego, S; Rodriguez, ML | 1 |
| Jang, HS; Kerkvliet, NI; Koch, DC; Kolluri, SK; Kopparapu, PR; O'Donnell, EF; Phillips, JL; Tanguay, RL | 1 |
| Chaubal, VA; Ito, S; Mojamdar, MV; Nair, SS; Wakamatsu, K | 1 |
| Carl, PL; Chakravarty, PK; Katzenellenbogen, JA; Weber, MJ | 1 |
13 other study(ies) available for isoxazoles and Malignant Melanoma
| Article | Year |
|---|---|
Preclinical Study of Immunological Isoxazole Derivatives as a Potential Support for Melanoma Chemotherapy.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line; Cell Movement; Cell Survival; Drug Evaluation, Preclinical; Glycoproteins; Humans; Isoxazoles; Melanoma; Reactive Oxygen Species; Skin Neoplasms | 2021 |
Search for immunomodulatory compounds with antiproliferative activity against melanoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Immunomodulating Agents; Isoxazoles; Melanoma | 2023 |
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
Topics: Animals; Catalytic Domain; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Drug Discovery; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isoxazoles; Macrophages; Melanoma; Mice; Microsomes; Natural Killer T-Cells; Transplantation, Isogeneic; Zebrafish; Zinc | 2019 |
Impact of Non-Steroidal Anti-Inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Female; Humans; Isoxazoles; Kaplan-Meier Estimate; Ketorolac; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Recurrence, Local; Perioperative Period; Piroxicam; Retrospective Studies; Sentinel Lymph Node Biopsy; Skin Neoplasms; Treatment Outcome | 2020 |
ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models.
Topics: Animals; Antineoplastic Agents; Catalytic Domain; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Isoxazoles; Macrophage Migration-Inhibitory Factors; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Phenols; Small Molecule Libraries; Spleen | 2014 |
Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity.
Topics: Adhesiveness; Administration, Cutaneous; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Stability; Emulsions; Excipients; Gels; Hardness Tests; Humans; Isoxazoles; Leflunomide; Melanoma; Nanostructures; Particle Size; Psoriasis; Skin Absorption; Viscosity | 2015 |
Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Heme Oxygenase-1; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Melanoma; Metalloporphyrins; Reactive Oxygen Species | 2015 |
2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Glutathione; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Isoxazoles; MAP Kinase Signaling System; Melanoma; Mice, SCID; Neoplasm Metastasis; NF-kappa B; Oxidation-Reduction; Oxidative Stress; Resorcinols; RNA, Messenger; Skin; Sulfonamides; Xenograft Model Antitumor Assays | 2016 |
DHODH modulates transcriptional elongation in the neural crest and melanoma.
Topics: Amino Acid Substitution; Animals; Animals, Genetically Modified; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Dihydroorotate Dehydrogenase; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Isoxazoles; Leflunomide; Melanoma; Mice; Neural Crest; Oxidoreductases Acting on CH-CH Group Donors; Proto-Oncogene Proteins B-raf; Rats; Stem Cells; Transcription, Genetic; Xenograft Model Antitumor Assays; Zebrafish | 2011 |
Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cytokines; Daunorubicin; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione; Humans; Isoxazoles; Melanoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Analysis; Xenograft Model Antitumor Assays | 2012 |
The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
Topics: Aniline Compounds; Cell Line, Tumor; Cell Proliferation; Crotonates; Cyclin-Dependent Kinase Inhibitor p21; Dihydroorotate Dehydrogenase; Fluoresceins; Gene Knockdown Techniques; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Melanoma; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Proto-Oncogene Proteins c-myc; Receptors, Aryl Hydrocarbon; Signal Transduction; Succinimides; Toluidines; Uridine | 2012 |
Gamma-glutamyl transpeptidase and its role in melanogenesis: redox reactions and regulation of tyrosinase.
Topics: Animals; Antimetabolites; Antineoplastic Agents; gamma-Glutamyltransferase; Hydrogen Peroxide; Isoxazoles; Melanoma; Mice; Monophenol Monooxygenase; NF-kappa B; Oxidation-Reduction; Oxidative Stress; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Survival; Cell Transformation, Neoplastic; Female; Fibrinolysin; Isoxazoles; Melanoma; Mice; Nitrogen Mustard Compounds; Oligopeptides; Ovarian Neoplasms; Oxazoles; Plasminogen Activators | 1983 |